Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | NPY1R | P25929 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12605203 | 0.84 | MEN1 (0.42) | MEN1KMT2AKDM4EALDH1A1GRIN2B | |
| SCHEMBL21120629 | 0.80 | OPRM1 (0.39) | MEN1KMT2AKDM4EGRIN2BPOLB | |
| SCHEMBL13181314 | 0.80 | OPRL1 (0.42) | MEN1KMT2A | |
| SCHEMBL24146229 | 0.78 | OPRL1 (0.45) | MEN1KMT2A | |
| SCHEMBL20386431 | 0.78 | OPRL1 (0.45) | MEN1KMT2A | |
| SCHEMBL11919059 | 0.77 | NCF1 (0.46) | MEN1KMT2AKDM4EALDH1A1GRIN2B | |
| SCHEMBL23384365 | 0.77 | NCF1 (0.46) | MEN1KMT2AKDM4EALDH1A1GRIN2B | |
| SCHEMBL178290 | 0.77 | — | — | |
| SCHEMBL25085633 | 0.75 | MEN1 (0.38) | MEN1KMT2AKDM4EALDH1A1GRIN2B | |
| SCHEMBL24294446 | 0.75 | MEN1 (0.38) | LMNAMEN1KMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021000899-A1 | A PHARMACEUTICAL COMBINATION CONTAINING mTOR INHIBITOR AND USE THEREOF | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2021-01-07 | — | — | WO | disclosed |